AMBU B Ambu A/S Class B

Ambu A/S: Capital increase in connection with exercise of warrants issued

Ambu A/S: Capital increase in connection with exercise of warrants issued

In December 2013, Ambu A/S issued 2,000,000 warrants, in December 2014 2,000,000 warrants and in December 2015 770,000 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 0.50. 52 individuals participate in the 2013 scheme, 22 individuals participate in the 2014-scheme and 46 individuals participate in the 2015 scheme. In all cases, the vesting period is three years, and all schemes can therefore be exercised in the trading window that opened on 1 May 2019 in connection with Ambu’s interim financial report for Q2 2018/19.





Attachment

EN
09/05/2019

Underlying

AMBU BAmbu A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

Free Trial
AMBU B Ambu A/S Class ...

Ambu AS: 1 director

A director at Ambu AS bought 12,500 shares at 118.560DKK and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

AMBU B AMBU A/S CLASS B
02/09/24 February 9, 2024 1 EN
 PRESS RELEASE
Free
AMBU B Ambu A/S Class ...

Ambu A/S: Reporting of transactions made by persons discharging manage...

Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.   The attached document discloses the data of the transactions made in Ambu shares.  Attachment

February 9, 2024 1 EN
 PRESS RELEASE
Free
AMBU B Ambu A/S Class ...

GRANT OF PERFORMANCE SHARE UNITS

GRANT OF PERFORMANCE SHARE UNITS Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 172,956 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2023/24 have been granted on 6 February 2024 with retroactive effect from 1 January 2024. 49,109 of the PSUs have been granted to the Executive Management and 123,847 of the PSUs have been granted to other key employees.  The LTIP covers the financial year 2023/24, and the final allocation of PSUs is conditional upon achievement of two key performance indicators (organic revenue growth and EBIT marg...

February 6, 2024 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
AMBU B Ambu A/S Class ...

Ambu (Buy, TP: DKK130.00) - Strong Q1 suggests promising 2024

With a c20% EBIT beat driven by the top line and profitability, Q1 showed Ambu is off to a strong start to 2023/24. However, the guidance was maintained and remains conservative in our view, while recent price rises to the legacy business and more reimbursement for the aScope 5 leave further upside potential. We reiterate our BUY and have raised our target price to DKK130 (120).

AMBU B AMBU A/S CLASS B
01/31/24 January 31, 2024 1 EN
 PRESS RELEASE
Free
AMBU B Ambu A/S Class ...

INTERIM REPORT FOR Q1 2023/24

INTERIM REPORT FOR Q1 2023/24 In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven by Endoscopy Solutions growing 25%, due to continued high double-digit growth within urology and ENT, combined with pulmonology growing 18%. “I am pleased with the performance within the first quarter of the year, showcasing our continued commitment to delivering strong profitable growth. With 25% growth in Endoscopy Solutions, an increased profitability level and a positive free cash flow of DKK 135m, we are off to a solid start ...

January 30, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch